This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Neogen Q1 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.
Company News for Oct 11, 2024
by Zacks Equity Research
Companies in The News Are: DAL,DPZ,NEOG,TXG
Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Neogen (NEOG) give a sense of how its business performed in the quarter ended August 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neogen (NEOG) Misses Q1 Earnings Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -30% and 0.39%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Neogen (NEOG) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Neogen (NEOG) for the quarter ended August 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -22.22% and 22.44%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Neogen (NEOG) Stock?
by Zacks Equity Research
Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge (INNV) delivered earnings and revenue surprises of 50% and 4.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Down 1.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen Suffers From Competitive Pressure, Macroeconomic Woes
by Zacks Equity Research
NEOG faces intense competition, which could affect the marketability and profitability of its products.
Is the Options Market Predicting a Spike in Neogen (NEOG) Stock?
by Zacks Equity Research
Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.
Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.
Neogen (NEOG) Lags Q4 Earnings Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -16.67% and 5.14%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial
by Zacks Equity Research
Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.
Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch
by Zacks Equity Research
Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.
Do Options Traders Know Something About Neogen (NEOG) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.
Neogen's (NEOG) MDS Secures New Contract From USDA FSIS
by Zacks Equity Research
Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.
Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Neogen (NEOG) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.
Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
by Zacks Equity Research
Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.
Neogen (NEOG) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing
by Zacks Equity Research
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
Company News for Apr 10, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, MRK, COIN, BN, NEOG
Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands
by Zacks Equity Research
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
Here's What Key Metrics Tell Us About Neogen (NEOG) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended February 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.